title: HIV antibody screening among immigrants: a cost-benefit analysis.
abstract: To assess the economic impact of HIV (human immunodeficiency virus) antibody screening among potential immigrants on Canada's health care system we estimated the costs and benefits of such screening among the 160 135 immigrants who entered Canada in 1988 using the in-hospital costs of treating AIDS (acquired immune deficiency syndrome) over the 10 years after immigration. This economic model was based on current international HIV seroprevalence data, Canadian immigration statistics and estimates of disease progression. Between 343 and 862 of the immigrants were estimated to have been HIV seropositive; with the use of the enzyme-linked immunosorbent assay and the Western blot technique 310 to 780 of them would have been correctly identified as being seropositive, and 33 to 82 would have been incorrectly classified as being seronegative. Another 16 would have been falsely classified as being seropositive. There would have been 151 to 379 cases of AIDS from 1988 to 1998 among the immigrants identified as being HIV-positive. The estimated total cost of screening would have been $3.3 to $3.4 million. The in-hospital costs of treating HIV-infected immigrants in whom AIDS developed between 1989 and 1998 would have been $5.0 to $17.1 million. Accordingly, screening would have saved $1.7 to $13.7 million over the 10 years after immigration. However, we do not advocate screening on the basis of economic analysis alone and acknowledge that any policy regarding such screening must also incorporate social, legal and ethical considerations.
authors.affiliation: Division of Clinical Epidemiology, Montreal General Hospital, PQ.
authors.forename: H
authors.initials: H
authors.lastname: Zowall
authors.forename: R D
authors.initials: RD
authors.lastname: Fraser
authors.forename: N
authors.initials: N
authors.lastname: Gilmore
authors.forename: A
authors.initials: A
authors.lastname: Deutsch
authors.forename: S
authors.initials: S
authors.lastname: Grover
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000191:economics* / Q000628:therapy; D015153:Blotting, Western; D002170:Canada / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D004641:Emigration and Immigration / Q000706:statistics & numerical data*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015483:HIV Antibodies / Q000032:analysis*; D006679:HIV Seropositivity / Q000175:diagnosis* / Q000191:economics; D015528:HIV Seroprevalence; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics*; D011237:Predictive Value of Tests
chemical_list: D015483:HIV Antibodies